Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-06-20
2006-06-20
Weddington, Kevin E. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S258100, C514S256000, C514S481000
Reexamination Certificate
active
07064130
ABSTRACT:
A method of treatment of the human or non-human animal body for treating NO-dependent microcirculation disorders is disclosed, for example microcirculation disorders caused by metabolic diseases, such as elevated levels of homocystin-homocystein inflammatory reactions or autoimmune diseases, furthermore peripheral microcirculation disorders or microcirculation disorders associated with increased cell fragmentation, which method comprises administering to a human or non-human animal body in need of such treatment an effective amount of a pharmaceutical composition containing a substance which scavenges free radicals, e.g. a pyrimido-pyrimidine selected from Dipyridamole, Mopidamol and the pharmaceutically acceptable salts thereof, and the use such substance for the manufacture of a corresponding pharmaceutical composition, optionally in combination with an agent capable of increasing NO procution.
REFERENCES:
patent: 5639482 (1997-06-01), Crary
patent: 5968983 (1999-10-01), Kaesemeyer
patent: 6015577 (2000-01-01), Eisert et al.
patent: 0 457 671 (1991-11-01), None
patent: 0 543 653 (1993-05-01), None
patent: 1 093 814 (2001-04-01), None
patent: WO 95 06470 (1995-03-01), None
patent: WO 00 677 37 (2000-11-01), None
Dukarm et al., “Pulmonary and systemic effects of the phosphodiesterase inhibitor dipyridamole in newborn lambs with persistent pulmonary hypertension”, Pediatric Research, vol. 44, pp. 831-837. (enclosed cpoy of abstract).
Steinhorn, R.; “Control and management of pulmonary vascular tone in the newborn”; J. of Children's Memorial Hospital Chicago; 2000.
Chen, H. et al; “Fluvastatin Upregulates Inducible Nitric Oxide Synthase Expression in Cytokine-Stimulated Vascular Smooth Muscle Cells”; Hypertension 2000: 36: 923.
Simons, M.; “Molecular multitasking: statins lead to more arteries, less plaque”; Nature Medicine, vol. 6, No. 9, 2000.
Laufs, U.; “Regulation of Endothelial Nitric Oxide Synthase Production by Inhibition of HMG-CoA Reductase”; INABIS '98.
Baller, D. et al; Verbesserung der koronaren Vasodilata-tionskapazitaet durch medikamentoese Lipid-senkung bei Patienten im Fruehstadium der koronaren Atherosklerose mit einge schraenkter Koronarreserve und maessig-gradiger LDL-Hypercholesterinaemie; Z Kardiol 87; Suppl 2, 136-144, 1998.
Baller, D. et al; (Translation) “Improvement of Coronary Vasodilator Capacity by Lipid-lowering Therapy in Patients in the Early Stage of Coronary Atherosclerosis with Reduced Coronary Reserve and Moderate LDL-Hypercholesterolemia”;Z Kardiol 87: Suppl 2, 136-144, 1998.
Marmont, et al; “Thrombotic Thrombocytopenic Purpura Successfully Treated WSith A Combination Of Dipyridamole And Aspirin”; Haematologica, 1980, 65 (2) 222-231.
Damad Study Group; “Effect of Aspirin Alone and Aspirin Plus Dipyridamole in Early Diabetic Retinopathy”; Diabetes, 1989, 38 (4), 491-498.
Connolly, et al; “Peripheral Vasodilators and the Management of Peripheral Vascular Disease and Raynaud's Syndrome in General Practice”; Pharmacoepidemiology and Drug Safety, 1998, 7, 189-196.
Kaiser, et al; “Short-term effect of dipyridamole on blood flow velocities in the extraocular vessels”; International Ophthalmology, 19, 6, 1996, 355-358.
Abstract: Derwent Pub. & SU 1 711 894 A (Kiev Child Clinic-2), Feb. 15, 1992.
Abstract: Derwent Pub. & SU 1 711 892 A (Mosc. Heamatology Blood Transfusion Inst.); Feb. 15, 1992.
Abstract: Denton, et al; “Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon” & Rheumatology (Oxford, England) England, 1999, vol. 38, No. 4.
Abstract: Sharma et al; “Probucol suppresses oxidant stress in hypertensive arteries. Immunohistochemical evidence.” & Am. J of Hypetension: J Am Soc of Hypertension. US, 1996, vol. 9, No. 6, 1996, 577-590.
Abstract: ADEE; “Managing Reynaud's phenomenon: a practical approach.”; & Am Family Phys. US; 1993, vol. 47, No. 4, 823-829.
Abstract: Ballmer, et al; “Antioxidant vitamins and disease—risk of a suboptimal supply!” & Therapeutische Umschau. Revue Therapeutique. Switzerland, 1994, vol. 51, No. 7, 467-474.
Abstract: Ali, et al; “Role of plasma ascorbate in diabetic microangiopathy.” & Bangladesh Medical Research Council Bulletin, Bangladesh, 1989, vol. 15, No. 2, 47-59.
Abstract: Yoshida, et al; “Effect of alpha-tocopherol, taurine and selenium on the attenuation of ischemia/reperfusion injury of splanchnic organs.”; & Cardiovascular Surgery (London, England) England, 1998, vol. 6, No. 2, 178-187.
Abstract: Kempski, et al; “Neuroprotection. Models and basic principles!”; & Der Anaesthesist. Germany, 1994, S25-S33.
Abstract: Langleben, et al; “Effects of dimethylthiourea on chronic hypoxia induced pulmonary arterial remodelling and ventricular hypertrophy in rats.”; & Clinical and Investigative Medicine. Medecine Clinique et Experimentale., Canada, 1989. vol. 12. No. 4. 235-240.
Abstract: Bertuglia, et al; “Glucose-insulin-potassium treatment in combination with dipyridamole inhibits ischaemia-reperfusion-induced damage.” & Diabetologia. Germany, 2001, vol. 44, No. 12, 2165-2170.
Boehringer Ingelheim Pharma GmbH & Co. KG
Devlin Mary-Ellen M.
Morris Michael P.
Weddington Kevin E.
Wittmayer Paula K.
LandOfFree
Use of radical-scavenging compounds for treatment and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of radical-scavenging compounds for treatment and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of radical-scavenging compounds for treatment and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3694412